Search results
Results from the WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
The primary current medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). These somatostatin analogues are synthetic forms of a brain hormone, somatostatin, which stops GH production. The long-acting forms of these drugs must be injected every 2 to 4 weeks for effective treatment.
This page was last edited on 6 September 2021, at 23:16 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Octreotide, lanreotide or pegvisomant Gigantism ( Greek : γίγας , gígas , " giant ", plural γίγαντες, gígantes ), also known as giantism , is a condition characterized by excessive growth and height significantly above average .
Bahasa Indonesia; Bahasa Melayu ... Lanreotide; M. Metreleptin; N. Norethisterone acetate; O. Octreotide; T. Tolvaptan This page was last edited on 13 July 2019, at ...
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lanreotide. PubMed provides review articles from the past five years (limit to free review articles)
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States [1] and the European Union [2] [3] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.